DE69834955D1 - Neue Verwendung von Budesonide und Formoterol - Google Patents

Neue Verwendung von Budesonide und Formoterol

Info

Publication number
DE69834955D1
DE69834955D1 DE69834955T DE69834955T DE69834955D1 DE 69834955 D1 DE69834955 D1 DE 69834955D1 DE 69834955 T DE69834955 T DE 69834955T DE 69834955 T DE69834955 T DE 69834955T DE 69834955 D1 DE69834955 D1 DE 69834955D1
Authority
DE
Germany
Prior art keywords
formoterol
budesonide
new use
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69834955T
Other languages
English (en)
Other versions
DE69834955T2 (de
Inventor
Carl-Axel Bauer
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69834955(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69834955D1 publication Critical patent/DE69834955D1/de
Application granted granted Critical
Publication of DE69834955T2 publication Critical patent/DE69834955T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69834955T 1997-09-19 1998-09-09 Neue Verwendung von Budesonide und Formoterol Revoked DE69834955T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use
SE9703407 1997-09-19

Publications (2)

Publication Number Publication Date
DE69834955D1 true DE69834955D1 (de) 2006-07-27
DE69834955T2 DE69834955T2 (de) 2007-01-25

Family

ID=20408325

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69834955T Revoked DE69834955T2 (de) 1997-09-19 1998-09-09 Neue Verwendung von Budesonide und Formoterol
DE69807239T Revoked DE69807239T2 (de) 1997-09-19 1998-09-09 Neue verwendung von budesonide und formoterol

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69807239T Revoked DE69807239T2 (de) 1997-09-19 1998-09-09 Neue verwendung von budesonide und formoterol

Country Status (38)

Country Link
US (2) US7897646B2 (de)
EP (2) EP1210943B1 (de)
JP (1) JP2001517630A (de)
KR (1) KR20010024140A (de)
CN (1) CN1149998C (de)
AR (1) AR013506A1 (de)
AT (2) ATE329599T1 (de)
AU (1) AU757235B2 (de)
BR (1) BR9812325A (de)
CA (1) CA2302700C (de)
CY (1) CY1106156T1 (de)
CZ (1) CZ295250B6 (de)
DE (2) DE69834955T2 (de)
DK (2) DK1014993T3 (de)
EE (1) EE04297B1 (de)
ES (2) ES2266322T3 (de)
HK (1) HK1045812B (de)
HU (1) HUP0003848A2 (de)
ID (1) ID24838A (de)
IL (1) IL134773A (de)
IN (1) IN190791B (de)
IS (1) IS2715B (de)
MX (1) MXPA00002615A (de)
MY (1) MY127812A (de)
NO (1) NO327176B1 (de)
NZ (1) NZ503173A (de)
PL (1) PL190782B1 (de)
PT (2) PT1014993E (de)
RU (1) RU2199322C2 (de)
SA (1) SA98190773B1 (de)
SE (1) SE9703407D0 (de)
SI (2) SI1014993T1 (de)
SK (1) SK285330B6 (de)
TR (1) TR200000726T2 (de)
TW (1) TW546140B (de)
UA (1) UA72446C2 (de)
WO (1) WO1999015182A1 (de)
ZA (1) ZA988516B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
ES2291452T3 (es) * 2001-02-06 2008-03-01 Innovata Biomed Limited Formulacion bimodal de polvo seco para inhalacion.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2006270165B2 (en) * 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111926T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
CN102869363A (zh) * 2010-01-15 2013-01-09 利赛拉公司 冻干的块状制剂
SG190878A1 (en) 2010-11-24 2013-07-31 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
WO2017093758A1 (en) 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2019287541A1 (en) 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3042866B2 (ja) 1989-09-08 2000-05-22 グラクソ・グループ・リミテッド 呼吸疾患治療薬
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
ATE213946T1 (de) 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
EP1086697A2 (de) 1991-12-18 2001-03-28 AstraZeneca AB Neue Verwendung von Budesonide und Formoterol
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
CA2238298A1 (en) * 1995-11-24 1997-06-19 Luca Francesco Raveglia Quinoline derivatives
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2002510310A (ja) 1997-06-27 2002-04-02 アストラ・アクチエボラーグ 抗喘息薬の新規配合
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
SK3892000A3 (en) 2000-12-11
SA98190773B1 (ar) 2006-10-02
SE9703407D0 (sv) 1997-09-19
PT1210943E (pt) 2006-09-29
IL134773A (en) 2005-03-20
IL134773A0 (en) 2001-04-30
ES2182357T3 (es) 2003-03-01
ATE329599T1 (de) 2006-07-15
PL190782B1 (pl) 2006-01-31
DE69834955T2 (de) 2007-01-25
NZ503173A (en) 2001-08-31
DK1210943T3 (da) 2006-09-18
EP1014993A1 (de) 2000-07-05
MY127812A (en) 2006-12-29
IS2715B (is) 2011-02-15
IS5407A (is) 2000-03-15
CN1271287A (zh) 2000-10-25
US20060189587A9 (en) 2006-08-24
US20110097282A1 (en) 2011-04-28
US8461211B2 (en) 2013-06-11
EE200000145A (et) 2001-02-15
CZ295250B6 (cs) 2005-06-15
DE69807239T2 (de) 2003-04-10
AU9192898A (en) 1999-04-12
MXPA00002615A (es) 2002-04-24
HUP0003848A2 (hu) 2001-08-28
CY1106156T1 (el) 2011-06-08
CZ2000950A3 (cs) 2000-06-14
EP1210943A1 (de) 2002-06-05
IN190791B (de) 2003-08-23
CN1149998C (zh) 2004-05-19
ES2266322T3 (es) 2007-03-01
DK1014993T3 (da) 2002-11-11
PL339295A1 (en) 2000-12-04
NO327176B1 (no) 2009-05-04
CA2302700A1 (en) 1999-04-01
WO1999015182A1 (en) 1999-04-01
US7897646B2 (en) 2011-03-01
HK1045812B (zh) 2006-12-22
AR013506A1 (es) 2000-12-27
HK1045812A1 (en) 2002-12-13
SI1014993T1 (en) 2003-02-28
JP2001517630A (ja) 2001-10-09
ZA988516B (en) 1999-03-19
TR200000726T2 (tr) 2000-09-21
BR9812325A (pt) 2000-09-05
PT1014993E (pt) 2002-12-31
EP1210943B1 (de) 2006-06-14
TW546140B (en) 2003-08-11
CA2302700C (en) 2010-11-23
EE04297B1 (et) 2004-06-15
ATE222106T1 (de) 2002-08-15
EP1014993B1 (de) 2002-08-14
UA72446C2 (uk) 2005-03-15
NO20001401L (no) 2000-03-17
US20020042404A1 (en) 2002-04-11
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
DE69807239D1 (de) 2002-09-19
NO20001401D0 (no) 2000-03-17
SK285330B6 (sk) 2006-11-03
SI1210943T1 (sl) 2006-10-31
ID24838A (id) 2000-08-24
AU757235B2 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
ATE222106T1 (de) Neue verwendung von budesonide und formoterol
DE59903869D1 (de) Verwendung von nanoskaligen sterolen und sterolestern
DE60010662D1 (de) Kombinationen von formoterol und fluticasonpropionat für asthma
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
ATE219329T1 (de) Neue verwendung von n-(phosphonomethyl)-glycin und derivaten davon
ATE218850T1 (de) Zusammensetzungen auf basis von sphingomyelinase und ihre verwendung
ATE241988T1 (de) Neue kombination von loteprednol und antihistaminika
DE69842004D1 (de) Substituierte 2-aminoacetamide und anwendung davon
DE69820397D1 (de) Ätzmittel und ihre Verwendung
DE69500727D1 (de) Klebstoffmischung und Faser-Gummi-Verbundwerkstoff
NO984094D0 (no) Utladningsreaktor og anvendelse av samme
DE69513307D1 (de) Zusammensetzung und verwendung
ID23822A (id) Pengangkatan kartu dan pengeluarannya
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
DE59703627D1 (de) Flüssigkeitszusammensetzung und verwendung der flüssigkeitszusammensetzung als magnetorheologische flüssigkeit
DE69806419T2 (de) Harzzusammensetzung und ihre Verwendung
DE69717677T2 (de) Koproduktion von perfluormethylperfluorvinylether und perfluorethylperfluorvinylether
DE69524590D1 (de) Zusammensetzung von 5htida und 5htid antagonisten
DE4494231T1 (de) Therapeutische Zusammensetzung und ihre Anwendung
DE955967T1 (de) Vorgefertigte orthese und verbundmaterial
DE69830259D1 (de) Gewebeschutzmittel und der Gebrauch desselben
DE69504049T2 (de) Neue progesteronverbindung und ihre verwendung
DE69732095D1 (de) Ionomerzusammensetzung und ihre verwendung
DE69803634D1 (de) Herstellung von Phenol und dessen Derivaten
DE69602782T2 (de) Klebstoffzusammensetzung und ihre Verwendung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation